Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year’s competition expands to seek broader digital solutions to local healthcare access challen…
Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the same indication as the reference medicine, to reduce the…
Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the same indication as the reference medicine, to reduce the…
Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic oral solids and Sandoz US dermatology businesses with appro…
Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic oral solids and Sandoz US dermatology businesses with appro…
Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treat…
Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treat…
Net sales grew 5% (cc[1], +7% USD) mainly driven by:Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EUEntresto sales more than doubled to USD 239 million, (+113% cc) driven by continued uptake worldwideOn…
Net sales grew 5% (cc[1], +7% USD) mainly driven by:Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EUEntresto sales more than doubled to USD 239 million, (+113% cc) driven by continued uptake worldwideOn…
Zessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1]Switching from the reference medicine to Erelzi® (etanercept) did not impact efficacy…